CDC-RFA-DP-24-0056: Building Capacity to Increase Commercial Tobacco Cessation
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCCDPHP notices from 2024.
Centers for Disease Control - NCCDPHP offered grants of up to $9.0 million (at least $225,000) to any type of organization. It expected to make about 3 awards worth $4.5 million in total. Applications closed on April 24, 2024.
From the official notice on Grants.gov, last changed February 21, 2024. Checked November 7, 2026.
- Award ceiling$9.0 million
- Award floor$225,000
- Total funding$4.5 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 21, 2024 |
|---|---|
| Deadline | April 24, 2024 |
| Archived by Grants.gov | May 24, 2024 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
N/A
Is this a realistic fit?
- Past Technical Assistance to Increase Tobacco Cessation awards averaged $675,000; this notice allows up to $9.0 million per award.
- Most of the program's money (100% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Commercial tobacco use remains the leading preventable cause of disease and death in the United States. More than half of people who smoke attempt to quit each year, but fewer than one in ten succeed. Proven cessation treatments that include individual, group, and telephone cessation counseling, seven Food and Drug Administration (FDA)-approved cessation medications, and web and text based interventions exist, but are underutilized. The Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health is announcing the opportunity to apply for funds for a competitive, non-research cooperative agreement aimed at building the capacity of state and territorial tobacco control programs and their partners to translate the science of tobacco cessation into public health interventions. These interventions are aimed at increasing the number of people who make an attempt to quit using tobacco products and who succeed in quitting. Training and technical assistance delivered through this funding will prioritize interventions that reach population groups disproportionately impacted by tobacco use and cessation-related disparities and be provided around the three goal areas for tobacco control programs’ cessation activities described in the 2014 edition of CDC’s Best Practices for Comprehensive Tobacco Control Programs. These include 1) Promoting health systems change to integrate evidence-based tobacco dependence treatment into routine clinical care; 2) Improving insurance coverage of evidence-based cessation treatments and increasing use of these treatments; and 3) Supporting state quitline capacity. This funding opportunity is projected to have a 60-month (5-year) period of performance with five 12-month budget periods. Each award (3 awards) is projected to have a 12-month budget of $300,000.
Who has won Technical Assistance to Increase Tobacco Cessation grants before
From fiscal 2021 to 2025, Technical Assistance to Increase Tobacco Cessation (93.348) awarded $1.4 million across 2 grant awards, an average of $675,000 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| American Lung Association | Illinois | 1 | $675,000 |
| North American Quitline Consortium | Arizona | 1 | $675,000 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DP-24-0056 still open?
No. It closed on April 24, 2024.
Who can apply for Building Capacity to Increase Commercial Tobacco Cessation?
Centers for Disease Control - NCCDPHP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Building Capacity to Increase Commercial Tobacco Cessation?
Closed April 24, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $9.0 million each. About $4.5 million in total across about 3 awards.
Who has won Technical Assistance to Increase Tobacco Cessation grants before?
The largest recipients over five fiscal years were American Lung Association, North American Quitline Consortium. The program made 2 awards worth $1.4 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)